

Leishmaniasis

*'The study of the cause of things must
be preceded by the study of things
caused.'*

Hughlings Jackson (1835-1911)

Definition & History

- **Infection by the protozoans of the genus Leishmania.**
- **Leishmaniasis may involve skin, mucus membranes, mouth, oropharynx and viscera.**
- **Early descriptions of the parasite in cutaneous lesions were by Cunningham, Borovsky, and Wright between 1885-1903.**

Definition & History


- In 1903 Leishman (top) and Donovan (bottom) separately described a visceral form.
- Identified organisms in the spleen.
- 1911--lesions of cutaneous leishmaniasis followed the sandfly bite.
- 1942--identified *L. donovani* in volunteers experimentally subjected to the bite of the sandfly.



Leishmaniasis-synonyms


- **Mucocutaneous**
 - “espundia”
- **Visceral**
 - “Kala-azar”
 - “dum-dum fever”
 - “espundia”
- **Cutaneous**
 - Delhi boil
 - Baghdad boil
 - Chiclero’s ulcer
 - Oriental sore,
 - Reta,
 - Year-long sore
 - Aleppo’s boil,
 - Biskara button,
 - Buton de Crete
 - Forest yaws
 - Pian bois
- **No vaccine**
- **However, infection with many of the species of Leishmania results in permanent immunity to reinfection with the same species.**

Geographic Distribution




***A few indigenous North American infections have been identified
In Texas. Bray, R.S. Leishmaniasis in the Old World. *Br. Med. Bull.*
1972:28:39-43**

Geographic Distribution



Geographic Distribution



With increased travel to endemic regions, diagnosis of leishmaniasis continues to challenge the clinician and pathologist.

Leishmania--Epidemiology

- **The number of humans infected difficult to determine.**
- **Conservative estimates suggest that several million are infected.**
- **More than 350 million live in within an area of transmission.**
- **Present in at least 88 countries.**


Leishmania--Epidemiology

- In the Eastern hemisphere, no less than fifteen species regularly infect people:
 - *L. leishmania amazonensis*
 - *L. viannia braziliensis*
 - *L. v. colombiensis*
 - *L. l. donovani*
 - *L. l. garnhami*
 - *L. v. guyanensis*
 - *L. l. infantum chagasi*
- *L. v. lainsoni*
- *L. v. lindenbergi*
- *L. l. mexicana*
- *L. v. naiffi*
- *L. v. panamensis*
- *L. l. pifanoi*
- *L. v. shawi*
- *L. l. venezualensis*

Leishmania--Epidemiology

- In the Western hemisphere, no less than fifteen species regularly infect people:
 - *L. I. donovani*
 - *L. I. infantum*
 - *L. I. aethiopica*
 - *L. I. major*
 - *L. I. tropica*
- As may be expected, clinical conditions caused by *Leishmania spp.* vary greatly, depending upon the species of *Leishmania* and the immune status (genetic make up) of the host.

Life Cycle



Like the Trypanosomes, *Leishmania* spp. are heteroxenous hemoflagellates.

Leishmaniasis – Vector



T. Evans © 1996

- Female** Sand fly
- *Phlebotomus spp.* (Old World)
 - *Lutzomyia spp.* (New World)

In Texas, the reservoir is the wood rat and the vector is *Lutzomyia anthophora*.

Some canines also have leishmaniasis.

Sandflies

- 1.5-5.5 mm long
- Transmission of human leishmaniasis is accomplished by less than 10% of the 600 known sandfly species.
- Nocturnal.




Sandflies

- Infection begins with the fly bite.
- Injects saliva containing numerous well-characterized bioactive components, e.g., **maxadilan** (a potent vasodilator).
- Leishmania inhibit fly regurgitation.
 - Increases chance of infection.




Leishmania spp. affect fly feeding mechanism

- Food ingested by action of 2 pumps—pharyngeal (ph) and cibarial (Ci).
 - Ca-Cardia
 - e-epithelial cells
 - m-sphincter muscle
 - Civ-cibarial valve
 - Cv-cardiac valve
 - H-host skin




There are 4 critical phases of development of the parasite in the insect vector:

- 1) Transformation of **amastigotes to promastigote** forms and rapid growth of the parasite occurs during blood meal digestion.
- 2) Migration out from the digested blood meal encased in the peritrophic matrix.
- 3) Binding of the parasite to the midgut epithelium and subsequent anterior migration of the parasites.
- 4) Transformation to the mammalian-infective form of the parasite (metacyclic promastigotes) and transfer during a subsequent feed.



Rosette Formation

- Occurs during the development of the metacyclic promastigote stage in the fly.
- Promastigotes bind to the gut tract via their flagella.




Promastigote—Binary fission

- **Flagellated metacyclic promastigote resides in the anterior midgut and thorax.**
- **Injected with fly saliva.**
 - **Maxadilan induced negative effects on host immune cell functions.**
 - **Interferes with IL-10 & TNF- α production.**
 - **Upregulates IL-6 production in macrophages.**
 - **Upregulates PGE2**




MØ Migration in the Skin

- Living promastigotes simulate MØ migration to the infection site.
- Antibody coated promastigotes utilize C3 to become phagocytised.





Leishmania--MØ

- **At the skin, differences between species of Leishmania become obvious.**
- **Those that cause only cutaneous lesions remain at the site throughout the infection.**
 - **Histiocytes**



Immune System Dynamics





Leishmaniasis and Th Responses




Mucocutaneous-Th2-humoral



Cutaneous-Th1-cellular

Skin lesion from a person with cutaneous leishmaniasis
(CDC/Dr. D.S. Martin).



**Visceral-Th1/Th2-Splenomegaly
(Amastigotes)**

Cutaneous Leishmaniasis

- Caused by 4 Old World and at least 15 New World species of *Leishmania*.
- **Oriental sore**—common in endemic areas of the Middle East, India, and Africa.
- A rudimentary form of vaccination referred to as “leishmanization” was practiced in the Middle East.
 - Controlled the region of the body where the scar developed.




Cutaneous Leishmaniasis

- **4 Types**
 - **Acute**
 - **Chronic**
 - **Diffuse cutaneous**
 - **Post kala-azar dermal leishmaniasis**

Cutaneous Leishmaniasis--**Acute**

- Pruritic papule develops at the site of inoculation.
- Well developed 2-8 weeks.
- Ulceration is followed by spontaneous healing in 3-12 months.
- Some lesions are papular or verrucous.



Cutaneous Leishmaniasis-- Chronic

- Rare.
- May present as an acute lesion but then persist (linger for years), resolve, or recur.



Cutaneous Leishmaniasis-- Diffuse

- Early lesion is shiny, erythematous nodule.
- Multiple nodules aggregate and coalesce, forming plaques.
- Dissemination occurs from these primary sites.
- Face, limbs, and buttocks may be involved.




Cutaneous Leishmaniasis—**Post kala-azar dermal leishmaniasis**

- PKDL
- 6% of treated patients develop skin lesions without history of re-exposure.
- 1-5 years after 1st exposure
- Hyperpigmented macules turn into firm nodules.
- Typically around mouth and nose (trunk and limbs too).
- Nodules composed of histiocytes.



2 years later—following therapy



Mucocutaneous Leishmaniasis


- **2-3% of *L. v. braziliensis* infections ‘metastasize’ to mucocutaneous junctions.**
 - Oral cavity
 - Urogenital
 - Anal areas
- **Infrequently *L. v. guyanensis* and *L. v. panamensis* cause similar disease.**

Mucocutaneous Leishmaniasis



Visceral Leishmaniasis (‘Kala-azar’)

- **Characterized by hepatosplenomegaly and high fever.**
 - **Progressive wasting**
 - **Death if untreated**
- **Primarily affects children.**
- **Latent period of 4-6 months (up to 10 years).**
- **More difficult to diagnose.**
- **Children with absent response to INF- γ had a 67% chance of developing visceral leishmaniasis.**
- **Called black fever because this describes the patients skin at the height of the infection.**
- **3-6 month incubation.**



Differential Diagnosis


- **Leishmania is identified microscopically within macrophages. It may resemble:**
 - *T. gondii*
 - *Histoplasma capsulatum* (same size and shape—distinguished using fungal stains).

Leishmaniasis – Diagnosis

- **Microscopy**
- **Biopsy**
 - Lesion, liver, spleen, bone marrow
- **PCR**
- **Serologic testing**
 - ELISA
 - Direct agglutination test

Leishmaniasis–Treatment

- Pentavalent antimonial drugs
 - Pentostam (**sodium stibogluconate**)
 - Glucantime
 - Aminosidine (Gabbromicina)
 - effective for cutaneous leishmaniasis, better tolerated
 - Humatin (paramomycin)
 - Severe toxic side effects with most antimonials
- Antifungals (ketoconazole, amphotericin B)
- Allopurinol
- Anticancer – Miltefosine (hexadecylphosphocholine)
 - 90% effective for visceral form



Sandfly

Mammalian Host

Promastigote

MΦ

DC

NK

Th1

Th2

B

Treg

MΦ

MΦ

MΦ

IL-12

IFN- γ

IL-10

TGF- β

IL-4

IL-4

IL-13

IL-10

TGF- β


CD4

V β 4V α 8

HEALING

NON-HEALING

Immune System Dynamics



How can infection with one pathogen exacerbate or diminish the symptoms caused by a second pathogen?



ELSEVIER

Available online at www.sciencedirect.com



Cellular Immunology xxx (2006) xxx–xxx

Cellular
Immunology

www.elsevier.com/locate/ycimm

Acute cysticercosis favours rapid and more severe lesions caused by
Leishmania major and *Leishmania mexicana* infection, a role
for alternatively activated macrophages

Miriam Rodríguez-Sosa ^a, Irma Rivera-Montoya ^a, Arlett Espinoza ^a,
Miriam Romero-Grijalva ^a, Roberto López-Flores ^b, Jorge González ^b, Luis I. Terrazas ^{a,*}



^a *Laboratory of Immunoparasitology, Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico*

^b *Carrera de Medicina, Facultad de Estudios Superiores Iztacala, Mexico*

Received 5 July 2006; accepted 18 September 2006





Lesion size following co-infection

- Lesions caused by both *L. major* and *L. mexicana* were exacerbated when co-infected with *Taenia crassiceps*.





Histologic exam of lesion in co-infected mice (skin)

- **A. *T. crassiceps*/*L. mexicana*.**
- **B. *L. mexicana* only.**
- **C. *T. crassiceps*/*L. major***
- **D. *L. major* only**
- **E. ???**




Parasite burdens in co-infected mice

- Parasite burdens from lymph nodes draining the site of infection.








Antibody response in singly and co-infected mice



a ○ *L. mexicana* ● *T. cruzi/L. mexicana*



d ○ *L. major* ● *T. cruzi/L. major*



Mounting a Response



Ultraviolet Light

- **UVA/UVB**
- **Immune suppression**
 - Local
 - systemic
- **Shifts IR from Th1 to Th2**
- **Upregulation of Th2 cytokines (keratinocytes).**



The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: Does ultraviolet light (UVB) radiation play a role? ☆

A. Ismail ^{a,*}, E.A.G. Khalil ^a, A.M. Musa ^a, I.M. EL Hassan ^b,
M.E. Ibrahim ^c, T.G. Theander ^d, A.M. EL Hassan ^a

^a Department of Clinical Pathology and Immunology, Faculty of Medicine, Institute of Endemic Diseases, University of Khartoum, Medical Sciences Campus, Qasr Street, Khartoum, Sudan

^b Department of Parasitology and Medical Entomology, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan


^c Department of Molecular Biology, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan

^d Institute of Medical Microbiology and Immunology, Center of Medical Parasitology, University of Copenhagen, Denmark

Received 14 January 2005; accepted 10 March 2005

- PKDL lesions mirror the clothing habits of patients.
- Lesions are confined to or are most severe in sun-exposed parts of the skin.
- Morphological and functional changes in Langerhans' cells that are found in PKDL lesions are compatible with the effects of UVB light.

Pathogenesis of PKDL



VL: Visceral Leishmaniasis
 LC: Langerhans Cells
 UV: Ultraviolet Light
 MØ: Macrophage
 PC: Paracortex
 PBL: Peripheral Blood Lymphocytes
 PKDL: Post Kala-azar Dermal Leishmaniasis
 AFF: Afferent
 EFF: Efferent
 NK: Natural Killer Cells

IDC: Interdigitating Cells
 TNF- α : Tumour Necrosis Factor Alpha
 TGF- β : Transforming Growth Factor Beta
 IFN- γ : Interferon Gamma
 Th1: T-helper -1
 Th2: T-helper-2
 IL-4: Interleukin-4
 IL-10: Interleukin-10
 IL-12: Interleukin-12